SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix Pharmaceuticals announced that safety and dosimetry data from…

Telix Pharmaceuticals Limited · PRESS-RELEASE filed Apr 21, 2026 at 16:49 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 21, 2026 at 16:49 ET

Telix Pharmaceuticals announced that safety and dosimetry data from Part 1 of its Phase 3 ProstACT Global trial for TLX591-Tx will be presented as a late-breaking oral presentation at the 2026 ASCO Annual Meeting. The selection for a high-profile session underscores the potential clinical relevance of its radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.

  • Safety and dosimetry data from Part 1 of the ProstACT Global Phase 3 trial will be presented at ASCO 2026 as a late-breaking oral presentation.
  • Part 1 included 36 patients and assessed tolerability, biodistribution, and radiation dose profile of TLX591-Tx in combination with standard of care.
  • TLX591-Tx shows reduced kidney toxicity and minimal salivary/lacrimal gland uptake compared to other PSMA-targeted therapies.
  • The abstract was selected for a high-visibility session at ASCO, indicating strong interest from the oncology community.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access